Rezetamig

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 18:47:57 GMT 2023` Edited by `admin` on `Sat Dec 16 18:47:57 GMT 2023`
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type	IGG4
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	M8FA2JKW5P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Rezetamig

Official Name

English

JNJ-75348780

Code

English

Immunoglobulin G4, anti-(human CD3 antigen) (recombinant human monoclonal JNJ-75348780 γ4-chain), disulfide with recombinant human monoclonal JNJ-75348780 κ chain, (229→126′),(232→129′)-bis(disulfide) with immunoglobulin, anti-(human sialic aci

Common Name

English

immunoglobulin half G4-kappa_G4(VH-h-CH2-CH3), anti-[Homo sapiens CD3E (CD3 epsilon)] and anti-[Homo sapiens CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14)], Homo sapiens monoclonal ant

Common Name

English

rezetamig [INN]

Common Name

English

JNJ75348780

Code

English

gamma4 heavy chain anti-CD3E Homo sapiens (1-450) [VH (Homo sapiens IGHV3-9*01 (98.0%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123)-Homo sapiens IGHG4*01, nG4m(a) CH2 L92, G4v5 h P10,G4v4 CH2 A1.3, A1.2,G4v32 CH3 W22 (knob) (

Common Name

English

Code System Code Type Description

CAS

2795115-07-8

Created by admin on Sat Dec 16 18:47:57 GMT 2023 , Edited by admin on Sat Dec 16 18:47:57 GMT 2023

PRIMARY

FDA UNII

M8FA2JKW5P

Created by admin on Sat Dec 16 18:47:57 GMT 2023 , Edited by admin on Sat Dec 16 18:47:57 GMT 2023

PRIMARY

INN

12767

Created by admin on Sat Dec 16 18:47:57 GMT 2023 , Edited by admin on Sat Dec 16 18:47:57 GMT 2023

PRIMARY

From	To
3_134	3_194
3_23	3_88
2_267	2_325
2_161	2_221
2_22	2_97
1_370	1_428
1_264	1_324
1_232	2_129
1_229	2_126
1_150	1_206
1_137	3_214
1_22	1_96

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_300
N	2_197

Related Record Type Details


					ZLW14X2D30

CD3

TARGET -> ACTIVATOR

Comments:

Pre-clinical

Amount:


					RCH7C9TW12

B-CELL RECEPTOR CD22

TARGET->LIGAND

Comments:

Pre-clinical

Amount:

Related Record Type Details


					M8FA2JKW5P

Rezetamig

ACTIVE MOIETY

Comments:

JNJ-75348780 (CD22xCD3) is a humanized IgG4-PAA bispecific antibody that can act as a bridge between CD22 positive malignant B-cells and CD3 positive cytotoxic T lymphocytes (CTLs), redirecting these immune effector cells and thereby promoting the lysis of malignant B-cells with a high degree of specificity

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL